Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance

Zhang, Haozhe; Yi, Zhou; Xing, Zengzhen; Sah, Rajiv Kumar; Hu, Junru; Hu, Hailiang

doi:10.3390/ijms232113521

Cited by 13 publications

(14 citation statements)

References 109 publications

(145 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Almost all treatments, from desensitized PCa (CSPC) to deadly resistant PCa (CRPC), target androgen metabolic pathways and AR. Altered androgen metabolism and its response are among the leading causes of drug resistance in PCa 127 . These findings further support the potential application of targeting PPAT-secreting molecules to control PCa progression.…”

Section: Ppat Provides New Perspectives For Diagnosing and Treating P...mentioning

confidence: 99%

Periprostatic Adipose Tissue: A New Perspective for Diagnosing and Treating Prostate Cancer

Cao,

Wang,

Zhang

et al. 2024

J. Cancer

View full text Add to dashboard Cite

Prostate cancer (PCa) is the most common tumor of the male genitourinary system. It will eventually progress to fatal metastatic castration-resistant prostate cancer, for which treatment options are limited. Adipose tissues are distributed in various parts of the body. They have different morphological structures and functional characteristics and are associated with the development of various tumors. Periprostatic adipose tissue (PPAT) is the closest white visceral adipose tissue to the prostate and is part of the PCa tumor microenvironment. Studies have shown that PPAT is involved in PCa development, progression, invasion, and metastasis through the secretion of multiple active molecules. Factors such as obesity, diet, exercise, and organochlorine pesticides can affect the development of PCa indirectly or directly through PPAT. Based on the mechanism of PPAT's involvement in regulating PCa, this review summarized various diagnostic and therapeutic approaches for PCa with potential applications to assess the progression of patients' disease and improve clinical outcomes.

show abstract

Section: Ppat Provides New Perspectives For Diagnosing and Treating P...mentioning

confidence: 99%

Periprostatic Adipose Tissue: A New Perspective for Diagnosing and Treating Prostate Cancer

Cao,

Wang,

Zhang

et al. 2024

J. Cancer

View full text Add to dashboard Cite

show abstract

“…For example, dimethylcurcumin (ASC-J9) induces degradation of the androgen receptors, including AR-V7 and AR-F876L, which are strongly associated with lacking sensitivity to therapy and metastasis during pancreatic cancer [337]. Its application sometimes decreases invasiveness of pancreatic cancer cells (Du145 and C4-2 cells), whereas this effect was significantly higher for AR-F876L positive cells [338].…”

Section: Future Directionmentioning

confidence: 99%

Therapeutic potential and limitations of curcumin as antimetastatic agent

Dytrych¹,

Kejík²,

Hajduch³

et al. 2023

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

“…However, the prognosis of locally advanced PC and PC with metastasis remains poor. Androgen deprivation therapy (ADT) is one of the main treatments of PC; however, most patients develop ADT resistance and castration-resistant prostate cancer (CRPC) within several years [ 4 , 5 ]. Available treatments for CRPC consist of chemotherapy or new-generation anti-androgen drugs; however, patients often develop drug resistance and poor prognosis [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Role of HIKESHI on Hyperthermia for Castration-Resistant Prostate Cancer and Application of a Novel Magnetic Nanoparticle with Carbon Nanohorn for Magnetic Hyperthermia

et al. 2023

View full text Add to dashboard Cite

The prognosis of castration-resistant prostate cancer (CRPC) is technically scarce; therefore, a novel treatment for CRPC remains warranted. To this end, hyperthermia (HT) was investigated as an alternative therapy. In this study, the analysis focused on the association between CRPC and heat shock protein nuclear import factor “hikeshi (HIKESHI)”, a factor of heat tolerance. Silencing the HIKESHI expression of 22Rv1 cells (human CRPC cell line) treated with siRNAs inhibited the translocation of heat shock protein 70 from the cytoplasm to the nucleus under heat shock and enhanced the effect of hyperthermia. Moreover, a novel magnetic nanoparticle was developed via binding carbon nanohorn (CNH) and iron oxide nanoparticle (IONP) with 3-aminopropylsilyl (APS). Tumor-bearing model mice implanted with 22 Rv1 cells were examined to determine the effect of magnetic HT (mHT). We locally injected CNH-APS-IONP into the tumor, which was set under an alternative magnetic field and showed that tumor growth in the treatment group was significantly suppressed compared with other groups. This study suggests that HIKESHI silencing enhances the sensitivity of 22Rv1 cells to HT, and CNH-APTES-IONP deserves consideration for mHT.

show abstract

Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance

Cited by 13 publications

References 109 publications

Periprostatic Adipose Tissue: A New Perspective for Diagnosing and Treating Prostate Cancer

Periprostatic Adipose Tissue: A New Perspective for Diagnosing and Treating Prostate Cancer

Therapeutic potential and limitations of curcumin as antimetastatic agent

Role of HIKESHI on Hyperthermia for Castration-Resistant Prostate Cancer and Application of a Novel Magnetic Nanoparticle with Carbon Nanohorn for Magnetic Hyperthermia

Contact Info

Product

Resources

About